(Albany, US), DelveInsight has launched a new report on CDKL5 Deficiency Disorder Market
DelveInsight’s Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder, historical and forecasted epidemiology as well as the Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Cyclin-Dependent Kinase-Like 5 Deficiency Disorder market report provides current treatment practices, emerging drugs, Cyclin-Dependent Kinase-Like 5 Deficiency Disorder market share of the individual therapies, current and forecasted Cyclin-Dependent Kinase-Like 5 Deficiency Disorder market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market
CDKL5 deficiency disorder is a rare developmental epileptic encephalopathy (DEE) caused by changes (mutations) in the CDKL5 gene. CDD has been classified as a DEE because the geneticchange causes both the epileptic activity as well as the severe impairment of development. Previously known as serine/threonine-protein kinase 9 (STK9), CDKL5 stands for cyclin-dependent kinase-like 5 and mutations in this gene were first identified as disease-causing in 2004. The hallmarks of CDD are the onset of seizures at a very early age, (usually about 3 months but can be as early as the first week of life) and severe neurodevelopmental delay impacting cognitive, motor, speech, and visual function. CDD can manifest in a broad range of clinical severity and is often associated with other symptoms such as gastrointestinal and sleep disturbances.
Request for free sample page:- https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market
Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Disease Treatment Algorithm
CDKL5 deficiency disorder (CDD) is a rare developmental epileptic encephalopathy (DEE), X-linked genetic condition which results in early-onset, difficult to control seizures and severe neuro-developmental impairment. CDKL5 stands for cyclin-dependent kinase-like 5 and mutations in this gene were first identified as disease-causing in 2004. CDD was previously not considered as a separate indication; rather, it was assumed to be an atypical form of Rett Syndrome.
The CDKL5 gene provides instructions for making proteins that are essential for normal brain and neuron development. The condition was previously known as serine/threonine-protein kinase 9 (STK9), and it has been classified as DEE because the genetic change causes epileptic activity as well as severe impairment of the development.
The CDKL5 gene is located on the X chromosome. The X chromosome is one of the sex chromosomes; females have two X’s, and males have one X and one Y chromosome. Although many identified patients are males, because of the location of the gene, this disorder mainly affects females. Affected males may have more severe symptoms than females
Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market Outlook
Currently, there are no approved therapies for CDD. The treatment landscape of CDD includes multidisciplinary care, including antiepileptic drugs, anticonvulsants, physiotherapy, occupational therapy, neurological speech therapy, and dietetics. Therapeutic methods in patients with CDD are based on symptomatic drug use to control the most problematic complaints that increase disability and to increase the possibility for the development of the individual patient. A multidisciplinary team approach is the most effective way to deliver necessary treatments aimed at maximizing the individual’s abilities and facilitating any skills that may be emerging. Emphasis should be placed on early intervention therapies such as physical therapy, occupational therapy, and speech and augmentative communication therapy. Important aspects of management include psychosocial support for the family, development of an appropriate education plan, and assessment of available community resources.
Seizures are a major problem for patients with CDD because they are usually severe and difficult to control with medication. No one anti-seizure medication has been found to be uniformly effective to treat CDD. A combination of anti-seizure medications may offer periods of seizure‐freedom lasting anywhere from a few weeks to a few years. Antiepileptic and anticonvulsants medications are given as the first-line treatment to the patients one by one, and if the seizures relapse in such a situation, second-line medications are preferred.
The CDD market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted CDD market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.
This segment gives a thorough detail of CDD market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market Insights
The biology of the CDKL5 protein and its deficiency is so poorly understood at present that there are currently significantly less investigational therapies being studied. The identification of causative mutations within the CDKL5 gene on the X chromosome has led to the proposal of several therapeutic strategies to treat and eventually cure the disorder. First, therapies to replace the mutated gene or protein with a functional version are being developed; this is an approach which has proven successful for certain diseases associated with the mutation of a single gene. Second, targeted genome editing to correct the mutation in affected cells has also been proposed, based on transformational technologies such as CRISPR-mediated site-directed DNA modification. Third, strategies are being investigated to target, in girls, the reactivation of the unmutated CDKL5 gene on the silenced X chromosome in a process called X reactivation. Finally, drug repurposing efforts are underway using bioinformatics and systems biology approaches to identify drugs developed for other diseases which might be effective against one or more of the symptoms of CDKL5 deficiency. Currently, no curative or specific therapies are available for individuals with the Cyclin-Dependent Kinase-Like 5 Deficiency Disorder, so medical management is symptomatic and supportive.
Table of content
1. Key Insights
2. Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Summary
3. Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Competitive Intelligence Analysis
4. Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Deficiency Disorder: Market Overview at a Glance
5. Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: Disease Background and Overview
6. Patient Journey
7. Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Epidemiology and Patient Population
8. Cyclin-Dependent Kinase-Like 5 Treatment Algorithm, Current Treatment, and Medical Practices
9. Cyclin-Dependent Kinase-Like 5 Deficiency DisorderUnmet Needs
10. Key Endpoints of Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Treatment
11. Cyclin-Dependent Kinase-Like 5 Marketed Products
12. Cyclin-Dependent Kinase-Like 5 Emerging Therapies
13. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Cyclin-Dependent Kinase-Like 5 Market Outlook
16. Access and Reimbursement Overview of Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder
17. KOL Views
18. Cyclin-Dependent Kinase-Like 5 Market Drivers
19. Cyclin-Dependent Kinase-Like 5 Market Barriers
21. DelveInsight Capabilities
23. About DelveInsight
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States